Paras Healthcare shares began trading on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) on October 28, 2026, at ₹720 per share, a 3.90% premium over the IPO issue price of ₹693. The healthcare provider’s market capitalization stood at approximately ₹7,790 crore following its listing, marking a positive but relatively modest debut for the hospital operator.
The company’s ₹1,450-crore initial public offering (IPO) received an overall subscription of approximately 2.23 times during the October 21–23 bidding period. Institutional demand was stronger than demand from non-institutional investors, while the retail portion was subscribed around twice. The listing gives public-market investors an opportunity to participate in a hospital network that operates across northern India, Bihar and Jharkhand.
Key Takeaways
- Listing price: Paras Healthcare debuted at ₹720 per share on both BSE and NSE.
- Listing gain: The opening price was 3.90% above the IPO issue price of ₹693.
- IPO size: The public issue raised approximately ₹1,450 crore through a fresh issue and an offer for sale.
- Subscription: The issue was subscribed approximately 2.23 times overall.
- Investor gain: A minimum lot of 21 shares represented a notional listing gain of ₹567 before charges.
- Business footprint: Paras Health operated eight hospitals with a combined capacity of 2,211 beds as of March 31, 2026.
- Use of proceeds: The company intends to use ₹375 crore of the fresh issue proceeds for debt repayment, with the remaining proceeds allocated to general corporate purposes.
Paras Healthcare IPO Listing: Price and Investor Returns
Paras Healthcare’s listing price of ₹720 was higher than its final IPO price of ₹693. The debut translated into an immediate gain for investors who received shares through the allotment process.
| Listing metric | Details |
|---|---|
| IPO issue price | ₹693 per share |
| BSE listing price | ₹720 per share |
| NSE listing price | ₹720 per share |
| Gain per share | ₹27 |
| Listing premium | 3.90% |
| Minimum lot size | 21 shares |
| Minimum investment at issue price | ₹14,553 |
| Value of one lot at listing | ₹15,120 |
| Notional gain per lot | ₹567 |
The ₹567 gain represents the difference between the allotment cost of 21 shares and their value at the listing price. It does not account for brokerage, taxes or other applicable charges, and it is not a guaranteed profit for investors who hold the shares beyond the opening trade.
The stock’s subsequent market price can move above or below the listing price as investors respond to trading demand, company performance and broader market conditions.
How Much Was the Paras Healthcare IPO Subscribed?
The IPO received a moderate overall response, with institutional investors providing the strongest demand. The final subscription data reported by Moneycontrol showed that the issue was subscribed approximately 2.23 times.
| Investor category | Subscription |
|---|---|
| Qualified institutional buyers (QIBs) | 3.09 times |
| Retail individual investors | 2.00 times |
| Non-institutional investors (NIIs) | 0.66 times |
| Overall subscription | 2.23 times |
The subscription figures indicate that demand varied significantly across investor categories. Qualified institutional buyers subscribed to their allocated portion more than three times, while non-institutional demand fell below the shares reserved for that category.
Retail investors subscribed approximately twice the available allocation, reflecting interest in the hospital operator despite uncertainty about the listing performance and future valuation.
Subscription levels are only one indicator of market interest. They do not establish whether a stock is attractively valued or predict how it will perform after listing.
Paras Healthcare IPO Structure and Fundraising
Paras Healthcare’s public issue was valued at approximately ₹1,450 crore. It comprised two components: a fresh issue of shares worth ₹500 crore and an offer for sale (OFS) worth ₹950 crore.
| IPO component | Amount | Recipient |
|---|---|---|
| Fresh issue | ₹500 crore | Paras Healthcare |
| Offer for sale | ₹950 crore | Selling shareholders |
| Total issue size | ₹1,450 crore | Combined offering |
The distinction matters because the proceeds from a fresh issue go to the company, while OFS proceeds go to the shareholders selling their existing shares. The entire ₹1,450 crore should therefore not be treated as new cash available to fund hospital operations or expansion.
According to the company’s IPO disclosures, ₹375 crore of the net fresh-issue proceeds is intended for repayment or prepayment of specified borrowings. The remaining proceeds are intended for general corporate purposes, subject to the offering documents.
Reducing debt can help lower interest expenses and improve financial flexibility. However, the actual effect depends on the company’s overall borrowing levels, operating cash flow and future capital requirements.
What Does Paras Healthcare Do?
Paras Healthcare operates hospitals under the Paras Health brand, focusing on tertiary and quaternary medical services. These services include complex and specialized treatments that often require advanced equipment, specialist doctors and multidisciplinary clinical teams.
As of March 31, 2026, the company operated eight hospitals with a combined capacity of 2,211 beds. Its facilities were located in Gurugram and Panchkula in Haryana; Patna and Darbhanga in Bihar; Kanpur in Uttar Pradesh; Udaipur in Rajasthan; Ranchi in Jharkhand; and Srinagar in Jammu and Kashmir.
The company focuses on clinical specialties including cardiac sciences, oncology, neuroscience, gastroenterology, orthopedics and renal sciences. Specialized services can support demand for complex treatment, although hospital performance also depends on doctor availability, patient volumes, occupancy rates and the ability to attract patients in competitive markets.
The company’s regional presence provides access to multiple healthcare markets, but its performance remains exposed to local competition, operating costs and the economics of running large hospital facilities.
Expansion Plans and Growth Opportunities
Paras Healthcare has identified hospital expansion as part of its longer-term growth strategy. Its disclosed plans include increasing capacity at existing facilities and developing additional hospitals through long-term lease arrangements.
The company’s investor disclosures identify a planned 300-bed facility in Gurugram and a new hospital in Ludhiana with capacity of up to 500 beds. The stated target dates were fiscal 2027 for the Gurugram facility and fiscal 2028 for Ludhiana.
Expansion could increase the number of patients the company can serve and strengthen its regional presence. However, new hospitals generally require spending on equipment, staffing, infrastructure and marketing before reaching mature occupancy levels.
Investors will need to track the progress of these projects, the capital required to bring them into operation and the pace at which new beds begin generating revenue. Delays, cost overruns or slower-than-expected patient growth could affect returns on the expansion investment.
What Investors Should Watch After the Listing
A positive debut is an initial market signal, not a complete assessment of a company’s long-term prospects. After listing, investors will have to evaluate Paras Healthcare’s financial performance and its ability to convert hospital capacity into sustainable earnings.
Several factors deserve attention:
- Revenue growth: Whether patient volumes, treatment mix and pricing support higher revenue.
- Hospital occupancy: Whether existing hospitals attract enough patients to use available capacity efficiently.
- Operating margins: Whether staff, equipment, maintenance and other expenses remain under control.
- Debt and interest costs: Whether planned repayments reduce borrowing expenses and strengthen the balance sheet.
- Expansion execution: Whether new hospitals open on schedule and reach sustainable utilization.
- Valuation: Whether the market price is justified by earnings, cash flow, growth prospects and comparisons with listed hospital operators.
Healthcare demand can benefit from long-term trends such as increasing access to specialized treatment and greater demand for advanced medical services. Yet these opportunities do not eliminate business risks or guarantee that a newly listed share will deliver attractive returns.
The Bigger Picture
Paras Healthcare’s debut adds another hospital operator to India’s listed healthcare sector. The 3.90% premium suggests that the stock opened above its IPO price, but the gain was limited enough that investors will likely look beyond the first trading session to assess the company’s prospects.
The company’s ability to repay debt, expand its hospital network and improve utilization will be important to its financial performance. For investors, the key question is whether future earnings and cash generation can justify the valuation established by the market after listing.
FAQs
1. At what price did Paras Healthcare shares list?
Paras Healthcare shares listed at ₹720 per share on both the BSE and NSE on October 28, 2026, representing a 3.90% premium over the IPO issue price of ₹693.
2. How much could an IPO investor gain per lot?
One lot contained 21 shares purchased at ₹693 each, costing ₹14,553. At the listing price of ₹720, the lot was worth ₹15,120, producing a notional gain of ₹567 before charges and taxes.
3. What was the total size of the Paras Healthcare IPO?
The IPO was valued at approximately ₹1,450 crore, comprising a ₹500-crore fresh issue and a ₹950-crore offer for sale by existing shareholders.
4. How much was the IPO subscribed?
The IPO received an overall subscription of approximately 2.23 times. Qualified institutional buyers subscribed 3.09 times, retail investors around 2 times and non-institutional investors 0.66 times, according to the reported figures.
5. What does Paras Healthcare plan to do with the fresh issue proceeds?
The company intends to use ₹375 crore of net fresh-issue proceeds to repay or prepay specified borrowings. The remaining proceeds are intended for general corporate purposes, according to its IPO disclosures.
Looking Ahead
The first trading session gave Paras Healthcare a positive market debut, but the stock’s longer-term performance will depend on business execution and financial results. Investors will be watching debt reduction, patient volumes, hospital occupancy and the company’s progress on planned expansion projects.
The listing also gives the company access to public capital markets as it seeks to grow its hospital network. Whether that growth translates into sustained shareholder value will depend on the company’s ability to manage costs, deploy capital efficiently and generate earnings that support its market valuation.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
